Sildenafil 50 Ananta tablets, film-coated, 50 mg each, No. 4

In stock: 3
$70.00

Ingredients

Active ingredient: sildenafil;

1 film-coated tablet contains sildenafil citrate equivalent to 50 mg or 100 mg of sildenafil;

Excipients: microcrystalline cellulose, anhydrous calcium hydrogen phosphate, croscarmellose sodium, magnesium stearate, Opadry II Blue 31K80956 (lactose monohydrate, hypromellose, titanium dioxide (E 171), triacetin, indigo carmine (E 132)), Opadry Clear 02K19253 (hypromellose, triacetin), purified water.

Dosage Form

Film-coated tablets.

Main physical and chemical properties:

50 mg tablets: blue, round, biconvex, film-coated tablets, embossed with “125” on one side and “J” and a score line on the other;

100 mg tablets: blue, round, biconvex, film-coated tablets, embossed with “126” on one side and “J” and a score line on the other.

Pharmacotherapeutic group

Agents used for erectile dysfunction.

ATC code G04B E03.

Pharmacological Properties

Pharmacodynamics.

Mechanism of action. Sildenafil is an oral medication indicated for the treatment of erectile dysfunction. During sexual arousal, the medication restores impaired erectile function by increasing blood flow to the penis.

The physiological mechanism underlying an erection involves the release of nitric oxide (NO) in the corpus cavernosum during sexual arousal. The released nitric oxide activates the enzyme guanylate cyclase, which stimulates an increase in the level of cyclic guanosine monophosphate (cGMP), which, in turn, causes the smooth muscles of the corpora cavernosa to relax, facilitating blood flow.

Sildenafil is a potent and selective inhibitor of cGMP-specific phosphodiesterase 5 (PDE5) in the corpora cavernosa, where PDE5 is responsible for the breakdown of cGMP. Sildenafil’s effect on erections is peripheral in nature. Sildenafil does not directly cause relaxation of isolated human corpus cavernosum tissues, but it potently enhances the relaxing effect of NO on this tissue. When the NO/cGMP metabolic pathway is activated—which occurs during sexual stimulation—sildenafil’s inhibition of PDE5 leads to an increase in cGMP levels in the corpora cavernosa. Thus, sexual arousal is necessary for sildenafil to produce the desired pharmacological effect.

Effect on Pharmacodynamics. In vitro studies have demonstrated the selectivity of sildenafil’s action on PDE5, which plays an active role in the erectile process. Sildenafil’s effect on PDE5 is more potent than its effect on other known phosphodiesterases. This effect is 10 times more potent than its effect on PDE6, which is involved in phototransduction processes in the retina. When administered at the maximum recommended doses, sildenafil’s selectivity for PDE5 is 80 times greater than its selectivity for PDE1, and is 700 times higher than its selectivity for PDE2, PDEZ, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11. In particular, sildenafil’s selectivity for PDE5 is 4,000 times greater than its selectivity for PDEZ—a cAMP-specific isoform of phosphodiesterase involved in the regulation of cardiac contractility.

Pharmacokinetics.

Absorption. Sildenafil is rapidly absorbed. Maximum plasma concentrations are reached within 30–120 minutes (with a median of 60 minutes) after oral administration on an empty stomach. The mean absolute bioavailability following oral administration is 41% (with a range of 25% to 63%). Within the recommended dose range (25 to 100 mg), the AUC and Cmax of sildenafil following oral administration increase proportionally with dose.

When sildenafil is taken with food, the rate of absorption decreases, with a mean prolongation of Tmax to 60 minutes and a mean reduction in Cmax of 29%.

Distribution. The mean steady-state volume of distribution (Vd) is 105 liters, indicating distribution of the drug into body tissues. Following a single oral dose of 100 mg of sildenafil, the mean maximum total plasma concentration of sildenafil is approximately 440 ng/mL (coefficient of variation is 40%). Since the binding of sildenafil and its major N-desmethyl metabolite to plasma proteins reaches 96%, the mean maximum plasma concentration of free sildenafil reaches 18 ng/mL (38 nmol). The degree of plasma protein binding does not depend on total sildenafil concentrations.

Data indicate that in healthy volunteers who received a single 100-mg dose of sildenafil, less than 0.0002% (an average of 188 ng) of the administered dose was detected in the ejaculate after 90 minutes.

Biotransformation. Sildenafil is metabolized primarily by the hepatic microsomal isoenzymes CYP3A4 (major pathway) and CYP2C9 (minor pathway). The major circulating metabolite is formed by N-demethylation of sildenafil. The metabolite’s selectivity for PDE5 is comparable to that of sildenafil, and the metabolite’s activity for PDE5 is approximately 50% of the parent compound’s activity. The plasma concentration of this metabolite is approximately 40% of the plasma concentration of sildenafil. The N-demethylated metabolite undergoes further metabolism, and its half-life is approximately 4 hours.

Elimination. The total clearance of sildenafil is 41 L/h, resulting in a half-life of 3–5 hours. Following both oral and intravenous administration, sildenafil is excreted as metabolites, primarily in the feces (approximately 80% of the administered oral dose) and, to a lesser extent, in the urine (approximately 13% of the administered oral dose).

Pharmacokinetics in Special Patient Populations.

Elderly patients. Data indicate that in healthy elderly volunteers (aged 65 years and older), a reduction in sildenafil clearance was observed, resulting in increased plasma concentrations of sildenafil and its active N-demethylated metabolite by approximately 90% compared with the corresponding concentrations in healthy younger volunteers (aged 18–45 years). Due to age-related differences in plasma protein binding, the corresponding increase in the plasma concentration of free sildenafil was approximately 40%.

Renal impairment. In patients with mild to moderate renal impairment (creatinine clearance 30 to 80 mL/min) the pharmacokinetics of sildenafil remained unchanged following a single 50-mg oral dose. The mean AUC and Cmax of the N-demethylated metabolite increased by 126% and 73%, respectively, compared with those in volunteers of the same age without renal impairment. However, due to high interindividual variability, these differences were not statistically significant. In volunteers with severe renal impairment (creatinine clearance below 30 mL/min) sildenafil clearance was reduced, resulting in mean increases in AUC and Cmax of 100% and 88%, respectively, compared with volunteers of the same age without renal impairment. In addition, the AUC and Cmax values of the N-demethylated metabolite increased significantly by 200% and 79%, respectively.

Hepatic impairment. In volunteers with mild to moderate liver cirrhosis (Child-Pugh classes A and B-Pugh classification), sildenafil clearance was reduced, resulting in increased AUC (84%) and Cmax (47%) compared with corresponding values in volunteers of the same age without liver dysfunction. The pharmacokinetics of sildenafil in patients with severe hepatic impairment have not been studied.

Indications

This medication is recommended for men with erectile dysfunction, defined as the inability to achieve or maintain an erection sufficient for successful sexual intercourse.

Sexual stimulation is required for the drug to be effective.

Contraindications

  • Hypersensitivity to the active ingredient or any of the drug’s excipients.
  • Concomitant use with nitric oxide donors (such as amyl nitrite) or nitrates in any form is contraindicated, as sildenafil is known to affect the nitric oxide/cyclic guanosine monophosphate (cGMP) metabolic pathways and potentiates the hypotensive effect of nitrates.
  • Concomitant use of PDE5 inhibitors (including sildenafil) with guanylate cyclase stimulators, such as riociguat, is contraindicated, as it may lead to symptomatic hypotension (see the “Drug Interactions and Other Interactions” section).
  • Conditions in which sexual activity is not recommended (e.g., severe cardiovascular disorders, such as unstable angina or severe heart failure).
  • Loss of vision in one eye due to non-arteritic anterior ischemic optic neuropathy, regardless of whether this condition is associated with prior use of PDE5 inhibitors.
  • Severe hepatic impairment, arterial hypotension (blood pressure below 90/50 mmHg), recent history of stroke or myocardial infarction, and known hereditary degenerative retinal disorders, such as retinitis pigmentosa (a small number of these patients have genetic disorders of retinal phosphodiesterases), since the safety of sildenafil has not been studied in these patient subgroups.

Drug Interactions and Other Interactions

Effects of other drugs on sildenafil.

Sildenafil is metabolized primarily by cytochrome P450 (CYP) isoform 3A4 (the major pathway) and isoform 2C9 (the minor pathway). Therefore, inhibitors of these isoenzymes may reduce the clearance of sildenafil, while inducers of these isoenzymes may increase the clearance of sildenafil.

A reduction in sildenafil clearance has been demonstrated when it is co-administered with CYP3A4 inhibitors (such as ketoconazole, erythromycin, and cimetidine). Although no increase in the incidence of adverse events was observed with the concomitant use of sildenafil and CYP3A4 inhibitors, the recommended starting dose of sildenafil is 25 mg.

Concomitant use of the HIV protease inhibitor ritonavir, a very potent P450 inhibitor, at steady-state concentrations (500 mg once daily) and sildenafil (a single 100-mg dose) resulted in a 300% (4-fold) increase in sildenafil Cmax and a 1,000% (11-fold) increase in sildenafil plasma AUC. After 24 hours, plasma levels of sildenafil were still approximately 200 ng/mL compared with a level of approximately 5 ng/mL, typical for sildenafil administered alone, which is consistent with ritonavir’s significant effect on a broad range of P450 substrates. Sildenafil does not affect the pharmacokinetics of ritonavir. Given these pharmacokinetic data, the concomitant use of sildenafil and ritonavir is not recommended; in any case, the maximum dose of sildenafil should under no circumstances exceed 25 mg within a 48-hour period.

Concomitant use of the HIV protease inhibitor saquinavir, a CYP3A4 inhibitor, at a dose that achieves steady-state concentrations (1,200 mg three times daily), and sildenafil (100 mg as a single dose) resulted in a 140% increase in sildenafil Cmax and a 210% increase in sildenafil systemic exposure (AUC). No effect of sildenafil on the pharmacokinetics of saquinavir was observed. It is anticipated that more potent CYP3A4 inhibitors, such as ketoconazole and itraconazole, will have a more pronounced effect.

When sildenafil (100 mg as a single dose) was administered with erythromycin, a moderate CYP3A4 inhibitor, at steady state (500 mg twice daily for 5 days), an increase in systemic sildenafil exposure of 182% (AUC) was observed. In healthy male volunteers, azithromycin (500 mg daily for 3 days) had no effect on the AUC, Cmax, Tmax, the elimination rate constant, or the terminal half-life of sildenafil or its major circulating metabolite. Cimetidine (a cytochrome P450 inhibitor and a nonspecific CYP3A4 inhibitor) at a dose of 800 mg, when co-administered with sildenafil at a dose of 50 mg in healthy volunteers, resulted in a 56% increase in plasma concentrations of sildenafil.

Grapefruit juice is a weak inhibitor of CYP3A4 in the intestinal wall and may cause a moderate increase in plasma levels of sildenafil.

A single dose of antacids (magnesium hydroxide/aluminum hydroxide) does not affect the bioavailability of sildenafil.

Although no specific interaction studies have been conducted with all medications, according to a population pharmacokinetic analysis, the pharmacokinetics of sildenafil were not altered when administered concomitantly with drugs belonging to the group of CYP2C9 inhibitors (tolbutamide, warfarin, phenytoin), the group of CYP2D6 inhibitors (such as selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants), thiazide and thiazide-like diuretics, loop and potassium-sparing diuretics, angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers, beta-adrenergic receptor antagonists, or CYP450 inducers (such as rifampin, barbiturates).

In a study involving healthy male volunteers, concomitant administration of the endothelin antagonist bosentan (a moderate inducer of CYP3A4, CYP2C9, and possibly CYP2C19) at steady state (125 mg twice daily) and sildenafil at steady state (80 mg three times daily) resulted in a 62.6% and 55.4% reduction in the AUC and Cmax of sildenafil, respectively. Therefore, concomitant use of potent CYP3A4 inducers such as rifampin may result in a more pronounced decrease in sildenafil plasma concentrations.

Nicorandil is a hybrid of a calcium channel activator and a nitrate. The nitrate component makes it capable of significant interaction with sildenafil.

Effects of sildenafil on other medications.

Sildenafil is a weak inhibitor of cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1, and 3A4 (IC50 > 150 μmol). Since peak plasma concentrations of sildenafil are approximately 1 μmol, the drug is unlikely to affect the clearance of substrates of these isoenzymes.

There are no data on the interaction between sildenafil and nonspecific phosphodiesterase inhibitors such as theophylline and dipyridamole.

Since sildenafil is known to affect the metabolism of nitric oxide/cyclic guanosine monophosphate (cGMP), it has been established that the drug potentiates the hypotensive effect of nitrates; therefore, its concomitant use with nitric oxide donors or with nitrates in any form is contraindicated.

Riociguat. Preclinical studies have demonstrated an additive systemic blood pressure-lowering effect when PDE5 inhibitors are used concomitantly with riociguat. Clinical studies have shown that riociguat enhances the blood pressure-lowering effect of PDE5 inhibitors. No positive clinical effect was observed in study participants when PDE5 inhibitors were used concomitantly with riociguat. The concomitant use of riociguat with PDE5 inhibitors (including sildenafil) is contraindicated (see the “Contraindications” section).

Concomitant use of sildenafil and alpha-adrenergic receptor blockers may lead to symptomatic hypotension in some susceptible patients. This reaction most often occurs within 4 hours after sildenafil administration. In specific drug interaction studies, the alpha-adrenergic receptor blocker doxazosin (4 mg and 8 mg) and sildenafil (25 mg, 50 mg, and 100 mg) were administered concomitantly to patients with benign prostatic hyperplasia whose condition had been stabilized with doxazosin. In these populations, an average additional reduction in blood pressure while the patient was lying down was observed of 7/7 mmHg, 9/5 mmHg, and 8/4 mmHg, respectively, and a mean reduction in blood pressure while standing of 6/6 mmHg, 11/4 mmHg, and 4/5 mmHg, respectively. When sildenafil was co-administered with doxazosin in patients whose condition had been stabilized with doxazosin, symptomatic orthostatic hypotension was occasionally reported. These reports described cases of dizziness and near-syncope, but without actual syncope.

No significant interactions were observed with the concomitant use of sildenafil (50 mg) and tolbutamide (250 mg) or warfarin (40 mg), which are metabolized by CYP2C9.

Sildenafil (50 mg) did not prolong bleeding time caused by acetylsalicylic acid (150 mg).

Sildenafil (50 mg) did not potentiate the hypotensive effect of alcohol in healthy volunteers at mean peak blood ethanol levels of 80 mg/dL.

In patients taking sildenafil, no differences in the adverse event profile were observed compared with placebo when sildenafil was co-administered with classes of antihypertensive drugs such as diuretics, beta-adrenergic receptor blockers, ACE inhibitors, angiotensin II antagonists, antihypertensive drugs (vasodilators and centrally acting agents), adrenergic neuron blockers, calcium channel blockers, and alpha-adrenergic receptor blockers. In a dedicated interaction study involving the concomitant use of sildenafil (100 mg) and amlodipine in patients with hypertension, an additional reduction in supine systolic blood pressure of 8 mmHg was observed. The corresponding decrease in diastolic blood pressure was 7 mmHg. In terms of magnitude, these additional decreases in blood pressure were comparable to those observed with sildenafil alone in healthy volunteers.

Sildenafil at a dose of 100 mg had no effect on the pharmacokinetic parameters of the HIV protease inhibitors saquinavir and ritonavir, which are CYP3A4 substrates.

In healthy male volunteers, sildenafil administration at steady state (80 mg three times daily) resulted in increases in the AUC and Cmax of bosentan (125 mg twice daily) by 49.8% and 42%, respectively.

Special Considerations for Use

Before starting therapy, a patient’s medical history should be taken and a physical examination performed to diagnose erectile dysfunction and determine its possible causes.

Risk factors for cardiovascular disease. Since sexual activity carries a certain risk to the heart, the physician should assess the patient’s cardiovascular status before initiating any treatment for erectile dysfunction. Sildenafil has a vasodilatory effect, which manifests as a mild and transient decrease in blood pressure. Before prescribing sildenafil, the physician should carefully consider whether this effect could have an adverse impact on patients with certain underlying medical conditions, especially when combined with sexual activity. Patients with increased sensitivity to vasodilators include those with left ventricular outflow tract obstruction (e.g., aortic stenosis, hypertrophic obstructive cardiomyopathy) or patients with the rare multisystem atrophy syndrome, one of the manifestations of which is severe autonomic dysregulation of blood pressure.

This drug potentiates the hypotensive effect of nitrates.

Serious adverse cardiovascular reactions have been reported, including myocardial infarction, unstable angina, sudden cardiac death, ventricular arrhythmia, cerebrovascular hemorrhages, transient ischemic attack, hypertension, and hypotension, which coincided with sildenafil administration. Most, but not all, of these patients had risk factors for cardiovascular disease. Many of these adverse reactions occurred during or immediately after sexual intercourse, and only a few occurred shortly after taking the drug without sexual activity. Therefore, it is impossible to determine whether the occurrence of these adverse reactions is directly related to risk factors or whether they are caused by other factors.

Priapism. Medications for the treatment of erectile dysfunction, including sildenafil, should be prescribed with caution to patients with anatomical deformities of the penis (such as angulation, cavernous fibrosis, or Peyronie’s disease) or to patients with conditions that predispose them to priapism (such as sickle cell anemia, multiple myeloma, or leukemia).

Cases of prolonged erection and priapism have been reported. If an erection lasts longer than 4 hours, patients should seek immediate medical attention. If not treated immediately, priapism can lead to damage to penile tissue and permanent loss of erectile function.

Concomitant use with other PDE5 inhibitors or other medications for the treatment of erectile dysfunction. The safety and efficacy of concomitant use of sildenafil with other PDE5 inhibitors or other medications for the treatment of pulmonary arterial hypertension that contain sildenafil, or with other medications for the treatment of erectile dysfunction, have not been studied. Therefore, the use of such combinations is not recommended.

Effects on vision. There have been spontaneous reports of visual disturbances associated with the use of sildenafil and other PDE5 inhibitors (see the “Adverse Reactions” section). Cases of non-arteritic anterior ischemic optic neuropathy, a rare condition, have been reported spontaneously and in an observational study as being associated with the use of sildenafil and other PDE5 inhibitors (see the “Adverse Reactions” section). Patients should be advised that if they experience sudden vision loss, they should stop taking the medication and seek immediate medical attention (see the “Contraindications” section).

Concomitant use with ritonavir. Concomitant use of sildenafil and ritonavir is not recommended (see the “Interactions with Other Medications and Other Interactions” section).

Concomitant use with α-adrenergic receptor blockers. Patients taking α-adrenergic receptor blockers should use sildenafil with caution, as this combination may cause symptomatic hypotension in some susceptible patients. Symptomatic hypotension usually occurs within 4 hours after sildenafil administration. To minimize the potential for postural hypotension in patients taking α-adrenergic receptor blockers, their condition should be stabilized with α-adrenergic receptor blockers prior to initiating sildenafil therapy. Consideration should also be given to using an initial dose of 25 mg (see the “Dosage and Administration” section). In addition, patients should be instructed on how to respond if symptoms of orthostatic hypotension occur.

Effect on Bleeding. Studies of human platelets have shown that, in vitro, sildenafil potentiates the antiplatelet effects of sodium nitroprusside. There is no information regarding the safety of sildenafil in patients with coagulation disorders or acute peptic ulcer disease. Therefore, sildenafil should be used in this patient group only after a careful assessment of the benefit-risk ratio.

The film coating of the tablets contains lactose monohydrate. The drug should not be used by men with rare hereditary disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

Fertility. Following administration of a 100-mg dose to healthy volunteers, no effects on sperm morphology or motility were observed.

Hearing loss. Physicians should advise patients to stop taking PDE5 inhibitors, including sildenafil, and to seek immediate medical attention in the event of a sudden decrease or loss of hearing. These events, which may also be accompanied by ringing in the ears and dizziness, have been reported in temporal association with the use of PDE5 inhibitors, including sildenafil-containing medications. It is not possible to determine whether these events are related to the use of PDE5 inhibitors or to other factors.

Concomitant use with antihypertensive medications. Sildenafil has a systemic vasodilatory effect and may further lower blood pressure in patients taking antihypertensive medications. In a separate drug interaction study involving the concomitant oral administration of amlodipine (5 mg or 10 mg) and sildenafil (100 mg), an average additional decrease in systolic blood pressure of 8 mmHg and diastolic blood pressure by 7 mmHg.

Sexually transmitted diseases. The use of sildenafil does not protect against sexually transmitted diseases. Consider advising patients on the necessary precautions to protect against sexually transmitted diseases, including human immunodeficiency virus.

Use during pregnancy or breastfeeding.

This medication is not intended for use by women.

Effect on reaction time when driving or operating machinery.

This medication may have a minor effect on the ability to drive or operate machinery. Since cases of dizziness and visual disturbances have been reported with sildenafil use, patients should determine their individual response to the drug before driving or operating machinery.

Dosage and Administration

Take this medication by mouth.

Adults.

The recommended dose is 50 mg, to be taken as needed approximately one hour before sexual activity. Depending on the drug’s effectiveness and tolerability, the dose may be increased to 100 mg or decreased to 25 mg. The maximum recommended dose is 100 mg. The maximum recommended dose should not be taken more than once daily. When taken with food, the drug’s effects may occur later than when taken on an empty stomach.

Elderly patients.

No dose adjustment is necessary for elderly patients (≥ 65 years of age).

Patients with renal impairment.

For patients with mild to moderate renal impairment (creatinine clearance 30 to 80 mL/min), the recommended dose is the same as that listed above in the “Adults” section.

Since sildenafil clearance is reduced in patients with severe renal impairment (creatinine clearance below 30 mL/min), the recommended dose is 25 mg. Depending on the drug’s efficacy and tolerability, the dose may be increased to 50 mg and 100 mg.

Patients with hepatic impairment.

Since sildenafil clearance is reduced in patients with hepatic impairment (e.g., cirrhosis), the recommended dose is 25 mg. Depending on the drug’s effectiveness and tolerability, the dose may be increased to 50 mg or 100 mg.

Patients taking other medications.

The recommended starting dose for patients taking CYP3A4 inhibitors—with the exception of ritonavir, which is not recommended for use with sildenafil—is 25 mg.

To minimize the risk of orthostatic hypotension, patients taking alpha-adrenergic receptor blockers should be stabilized before starting sildenafil. The recommended starting dose of sildenafil is 25 mg.

Children.

This medication is not indicated for use in individuals under 18 years of age.

Overdose

When a single dose of sildenafil up to 800 mg was administered, adverse reactions were similar to those observed with lower doses of sildenafil but occurred more frequently and were more severe. A 200-mg dose of sildenafil did not increase efficacy, but did result in an increase in the incidence of adverse reactions (headache, flushing, dizziness, dyspepsia, nasal congestion, and visual disturbances).

In case of overdose, standard supportive measures should be taken as needed. Accelerated clearance of sildenafil during hemodialysis is unlikely due to the drug’s high degree of binding to plasma proteins and the absence of sildenafil excretion in urine.

Side Effects

The most commonly reported adverse reactions include headache, flushing, dyspepsia, nasal congestion, back pain, dizziness, nausea, hot flashes, visual disturbances, cyanopsia, and blurred vision.

Adverse reactions are listed below according to the “System-Organ-Class” classification and frequency: very common (≥ 1/10), common (≥ 1/100 – < 1/10), uncommon (≥ 1/1,000 – < 1/100), and rare (≥ 1/10,000 – < 1/1,000). Within each frequency group, adverse reactions are listed in order of decreasing incidence.

Infections and infestations.

Uncommon: rhinitis.

Immune system disorders.

Uncommon: hypersensitivity.

Nervous system disorders.

Very common: headache.

Common: dizziness.

Uncommon: drowsiness, hypoesthesia.

Rare: stroke, transient ischemic attack, seizures*, recurrent seizures*, syncope.

Eye disorders.

Common: color vision abnormalities**, visual disturbances, blurred vision.

Uncommon: lacrimation disorders***, eye pain, photophobia, photopsia, ocular hyperemia, visual brightness, conjunctivitis.

Rare: non-arteritic anterior ischemic optic neuropathy*, retinal vascular occlusion*, retinal hemorrhage, arteriosclerotic retinopathy, retinal disorders, glaucoma, visual field defects, diplopia, decreased visual acuity, myopia, asthenopia, floating vitreous opacities, iris disorders, mydriasis, halos around light sources in the visual field, eye swelling, puffiness of the eyes, eye disorders, conjunctival hyperemia, eye irritation, abnormal sensations in the eyes, eyelid swelling, scleral discoloration.

Ear and vestibular system disorders.

Uncommon: dizziness, ringing in the ears.

Rare: deafness.

Cardiac disorders.

Uncommon: tachycardia, palpitations.

Rare: sudden cardiac death*, myocardial infarction, ventricular arrhythmia*, atrial fibrillation, unstable angina.

Vascular system.

Common: flushing, hot flashes.

Uncommon: hypertension, hypotension.

Respiratory, thoracic, and mediastinal disorders.

Common: nasal congestion.

Uncommon: nosebleeds, sinus congestion.

Rare: sensation of tightness in the throat, swelling of the nasal mucosa, dryness in the nose.

Gastrointestinal system.

Common: nausea, dyspepsia.

Uncommon: gastroesophageal reflux disease, vomiting, upper abdominal pain, dry mouth.

Rare: oral hypesthesia.

Skin and subcutaneous tissue disorders.

Uncommon: rash.

Rare: Stevens-Johnson syndrome*, toxic epidermal necrolysis*.

Musculoskeletal and connective tissue disorders.

Uncommon: myalgia, pain in the extremities.

Urinary system.

Uncommon: hematuria.

Reproductive system and mammary glands.

Rare: penile bleeding, priapism*, hematospermia, prolonged erection.

General disorders and administration site conditions.

Uncommon: chest pain, increased fatigue, feeling of heat.

Rare: irritation.

Examination.

Uncommon: increased heart rate.

* Reported only during postmarketing studies of sildenafil.

** Color vision abnormalities: chloropsia, chromatopsia, cyanopsia, erythropsia, xanthopsia.

*** Abnormal tear production: dry eyes, decreased tear production, and increased tear production.

The following events were observed in < 2% of patients during clinical trials; a causal relationship has not been established. Reports included events that had a probable association with sildenafil use. Events not listed were mild, and the reports were too vague to be meaningful.

General: facial edema, photosensitivity reactions, shock, asthenia, pain, sudden fall, abdominal pain, sudden injury.

Cardiovascular system: angina pectoris, AV block, migraine, postural hypotension, myocardial ischemia, cerebral thrombosis, sudden cardiac arrest, ECG abnormalities, cardiomyopathy.

Gastrointestinal system: glossitis, colitis, dysphagia, gastritis, gastroenteritis, esophagitis, stomatitis, abnormal liver function test results, rectal bleeding, gingivitis.

Blood and lymphatic system disorders: anemia, leukopenia.

Metabolic and nutritional disorders: thirst, edema, gout, unstable diabetes, hyperglycemia, peripheral edema, hyperuricemia, hypoglycemia, hypernatremia.

Musculoskeletal system: arthritis, osteoarthritis, tendon rupture, tenosynovitis, bone pain, myasthenia gravis, synovitis.

Nervous system disorders: ataxia, neuralgia, neuropathy, paresthesia, tremor, vertigo, depression, insomnia, abnormal dreams, decreased reflexes.

Respiratory system: asthma, dyspnea, laryngitis, pharyngitis, sinusitis, bronchitis, increased salivation, worsening of cough.

Skin disorders: hives, herpes, itching, sweating, skin ulcers, contact dermatitis, exfoliative dermatitis.

Sensory symptoms: sudden hearing loss or impairment, ear pain, hemorrhage in the eye, cataracts, dry eyes.

Urogenital system: cystitis, nocturia, increased urinary frequency, breast enlargement, urinary incontinence, ejaculatory dysfunction, genital edema, anorgasmia.

Adverse reactions reported from a population of unknown size. These events were noted due to their severity, frequency of reporting, the absence of a clear alternative cause, or a combination of these factors.

Cardiovascular and cerebrovascular events. Serious cardiovascular, cerebrovascular, and vascular events have been reported, including cerebrovascular hemorrhage, subarachnoid and intracerebral hemorrhage, and pulmonary hemorrhage, which were temporally associated with sildenafil use. Most, but not all, of these patients had cardiovascular risk factors. Many of these events were reported to have occurred during or immediately after sexual activity, and a few events occurred immediately after sildenafil administration without sexual activity. Other events occurred within the following hours or days after sildenafil administration and sexual activity. It is not possible to determine whether these events are related to sildenafil use, sexual activity, pre-existing risk factors, a combination of these factors, or other factors.

Cardiovascular and lymphatic system: vaso-occlusive crisis. In a small, prematurely terminated study of sildenafil in patients with pulmonary arterial hypertension secondary to sickle cell anemia, the occurrence of vaso-occlusive crises requiring hospitalization was reported more frequently with sildenafil than with placebo. The clinical significance of this information for patients using the drug to treat erectile dysfunction is unknown.

Nervous system disorders: anxiety, transient global amnesia.

Sensory disturbances.

Ear disorders. Cases of sudden hearing loss or impairment, temporally associated with sildenafil use, have been reported. In some cases, underlying medical conditions and other factors that could have contributed to the development of auditory adverse reactions were reported. In many cases, information regarding follow-up medical observation is lacking. It is impossible to determine whether these events are directly related to sildenafil use, to existing risk factors for hearing loss, to a combination of these factors, or to other factors.

Ocular adverse reactions: temporary vision loss, redness of the eyes, burning sensation in the eyes, increased intraocular pressure, retinal edema, retinal vascular disorders or hemorrhage, and vitreous detachment.

Cases of non-arteritic anterior ischemic optic neuropathy, resulting in vision loss, including permanent vision loss, have been reported and were temporally associated with the use of PDE5 inhibitors, including sildenafil. Many, but not all, patients had anatomical or vascular risk factors for non-arteritic anterior ischemic optic neuropathy, including (but not limited to) the following: a low cup-to-disc ratio (congestive optic disc), age 50 years or older, hypertension, coronary artery disease, hyperlipidemia, and smoking. It is not possible to determine whether these phenomena are directly related to the use of PDE5 inhibitors, to existing anatomical or vascular risk factors, to a combination of all these factors, or to other factors.

Reporting of Suspected Adverse Reactions. Reporting of suspected adverse reactions after the drug’s approval is of great importance. This allows for continuous monitoring of the benefit-risk profile associated with the use of this drug. Physicians should report any suspected adverse reactions in accordance with legal requirements.

Shelf life

2 years.

Storage Conditions

Store in the original packaging, out of the reach of children, at a temperature not exceeding 25 °C.

Packaging

4 tablets per blister, 1 blister per pack.

1 tablet per blister, 1 blister per pack.

Manufacturer

Arthura Pharmaceuticals Pvt. Ltd.

Manufacturer’s location and address of its place of business.

1505 Portia Road, Sri City SEZ, Setiyawedu Mandal, Chittoor District - 517 588, Andhra Pradesh, India.

Applicant

Ananta Medicair Ltd.

Location of the applicant and/or the applicant’s representative.

Suite 1, 2 Station Court, Imperial Wharf, Townmed Road, Fulham, London, United Kingdom.